INTRODUCTION
Long-term complete suppression of HBV replication by nucleos(t)ide analogue (NUC) therapy is associated with reduced risk of mortality and/or hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). [1] [2] [3] [4] [5] [6] [7] [8] [9] The availability of potent NUCs, such as entecavir (ETV) and tenofovir disoproxil fumarate (TDF), which have a
Significance of this study
What is already known on this subject?
▸ Once antiviral-resistant HBV mutants have been selected, they are retained in the virus population for a period of time (up to 12-18 months) after antiviral therapy is discontinued. ▸ The rate of entecavir (ETV) resistance increases up to 51% after 5 years of ETV treatment in patients with lamivudine-resistant HBV, which is in striking contrast to a 1.2% resistance rate in nucleos(t)ide analogue-naive patients. ▸ In vitro studies suggest that ETV-resistant HBV mutants are susceptible to tenofovir disoproxil fumarate (TDF).
What are the new findings?
▸ The proportion of patients with virological response and the mean change in HBV DNA levels from baseline were not significantly different between the TDF and TDF+ETV groups at week 48. ▸ Few patients in both treatment groups retained their baseline resistance mutations at week 48. None developed additional resistance mutations. ▸ Previous exposure to adefovir dipivoxil (ADV) and high HBV DNA level at baseline were significantly associated with lower rate of virological response at 48 weeks. However, the addition of ETV to TDF did not increase the rate of virological response compared with TDF monotherapy.
How might it impact on clinical practice in the foreseeable future?
▸ TDF monotherapy may be a reasonable and safe treatment option for patients with ETV-resistant HBV. ▸ TDF monotherapy would be superior to combination therapies based on ADV in ETV-resistant patients in terms of virological response and prevention of additional resistance.
minimal risk of drug resistance, has enabled reduction of serum HBV DNA to levels undetectable by PCR assays in most treatment-naive patients. 10 11 However, many patients commenced antiviral treatment with the less potent first-generation NUC, lamivudine (LAM), which has a low genetic barrier to resistance. Once antiviral-resistant HBV mutants have been selected, they are persistently retained in the virus population even if treatment is stopped. [12] [13] [14] In patients with LAM-resistant HBV, the rate of ETV resistance increases up to 51% after 5 years of ETV treatment, which is in striking contrast to a 1.2% resistance rate in NUC-naive patients. 15 16 This difference is because the ETV resistance barrier is lowered by the initial selection of the LAM-resistant HBV mutation, rtM204V/I. 17 In vitro studies have shown that susceptibility to ETV decreases by 10-fold to 250-fold when one of the ETV resistance-associated substitutions at rtT184, rtS202 or rtM250 is present in combination with rtM204V/I and by >500-fold when two or more of these mutations are present. 15 17 In vitro studies suggest that ETV-resistant HBV mutants are susceptible to adefovir dipivoxil (ADV) and TDF. 13 18 However, no clinical trial data are available, and only a few cohort studies have reported the efficacy of ADV or TDF in patients with ETV-resistant HBV. [19] [20] [21] [22] The cohort studies include a small number of patients with ETV-resistant HBV, and report mixed results on the efficacy of TDF monotherapy, and TDF plus ETV, or ADV plus ETV, combination therapies. Therefore, there is no consistent treatment recommendation for patients harbouring ETV-resistant HBV. For example, the American Association for the Study of Liver Diseases recommends switching to ADV or TDF monotherapy, 12 whereas the European and Asian-Pacific guidelines recommend switching to or adding TDF to ETV for patients with ETV resistance. 23 24 However, the evidence levels of these recommendations are low as a result of the limited clinical data.
In this randomised trial, we aimed to compare the efficacy of TDF monotherapy with that of TDF and ETV combination therapy in patients with documented ETV-resistant HBV mutations and persistent viraemia.
PATIENTS AND METHODS Study design
The study was a multicentre randomised open-label 48-week trial (ClinicalTrials.gov ID NCT01639092) conducted in patients who had persistent HBV viraemia with documented genotypic resistance to ETV (rtT184A/C/F/G/I/L/S, rtS202G, or rtM250L/V, in addition to rtM204V/I). Patients were randomised (in a 1:1 ratio using a centralised procedure and an interactive web response system) to receive either TDF 300 mg once daily (TDF group) or a combination of TDF 300 mg and ETV 1 mg once daily (TDF+ETV group). Treatment assignments were generated in a block size of four.
The study was conducted in compliance with all regulatory obligations and the Institutional Review Board of each investigational site.
Study subjects
Patients were enrolled between September 2012 and August 2013 from five centres in Korea. Patients with CHB (defined as a positive serum hepatitis B surface antigen (HBsAg) test for at least 6 months) were eligible for enrolment if they had serum HBV DNA levels >60 IU/mL at screening, were currently receiving any NUC other than TDF and were confirmed to have genotypic resistance to ETV (the presence of rtT184A/C/F/G/I/ L/S, rtS202G or rtM250L/V, in addition to rtM204V/I). Patients were required to be between 20 and 75 years old and to have serum creatinine levels <1.5 mg/dL. Prior and/or ongoing LAM, ETV and ADV therapy in any combination was permitted and prior interferon therapy was allowed if treatment was discontinued at least 12 months before screening. Patients with resistance mutations to ADV (rtA181V/T and/or rtN236T) documented before or at screening, prior exposure to TDF for >1 week, evidence of decompensated liver disease, any malignant neoplasm or coinfection with hepatitis C, hepatitis D or HIV were excluded.
Efficacy and safety measures
The primary efficacy endpoint was the proportion of patients who achieved a virological response (serum HBV DNA <15 IU/ mL) at week 48. Secondary endpoints included the proportion of patients with serum HBV DNA levels <60 IU/mL, the change in serum HBV DNA levels from baseline, the proportion of patients with normal alanine aminotransferase (ALT) and the proportion of patients with hepatitis B e antigen (HBeAg) loss/ seroconversion (HBeAg-positive patients only) and HBsAg loss/ seroconversion at week 48. The incidence of virological breakthrough (increases in HBV DNA levels ≥1 log 10 IU/mL from nadir on two consecutive tests) was evaluated. The cumulative probability of developing resistance was evaluated by genotypic analysis for all patients who experienced virological breakthrough or persistent viraemia (ie, HBV DNA >60 IU/mL) by the last time point of treatment.
Adverse events (clinical and laboratory) were assessed throughout the 48 weeks. Estimated glomerular filtration rate (eGFR) was estimated by using the modification of diet in renal disease (MDRD) equation. 25 Bone mineral density (BMD) measurements of the lumbar spine and femur were determined via dual-energy X-ray absorptiometry (DXA) at baseline and at 48 weeks.
Adherence to study drugs was assessed by counting the number of pills and empty blister packets returned at each visit.
Serum assays
Serum HBV DNA levels were measured using a real-time PCR assay (linear dynamic detection range, 15 to 1×10 9 IU/mL; Abbott Laboratories, Chicago, IL, USA). HBV genotype was determined by restriction fragment mass polymorphism (RFMP) analysis. Antiviral drug resistance mutations were determined by RFMP analyses 26 27 and direct sequencing of the reverse transcriptase region of the HBV polymerase gene ( pol/RT). Sequencing was performed on PCR products amplified from patient sera using the standard protocol for the ABI 3130 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA).
Statistical analyses
The primary dataset for efficacy and safety analyses was defined as all randomised patients (intention-to-treat analysis). Patients who discontinued the study prior to week 48 were considered failures for all endpoints after the time of discontinuation.
The primary efficacy endpoint was the proportion of patients with a virological response at week 48. Assuming success rates of 85% for both TDF and TDF+ETV groups, and a one-sided 10% non-inferiority margin, and taking into account a dropout rate of up to 5%, the sample size needed to achieve 80% power was 90 patients in total and 45 patients per arm, based on a test for non-inferiority of proportions. This sample size would also provide 99% power to detect a between-group difference in mean HBV DNA levels of 1 log 10 IU/mL, assuming a within-group SD of 1 log 10 IU/mL and a one-sided significance level of 0.025.
Between-group comparisons of continuous or categorical variables were conducted using a t test, χ 2 test or Fisher's exact test, as appropriate. Baseline factors predictive of virological response were evaluated by binary logistic regression analysis. All statistical analyses were performed using SPSS (V.20, SPSS, Chicago, IL, USA) and R (V.3.0, http://cran.r-project.org/). A p value <0.05 was considered statistically significant.
RESULTS Patients
A total of 90 patients were randomised to receive TDF monotherapy (TDF group, n=45) or TDF plus ETV combination therapy (TDF+ETV group, n=45), with 44 and 45 patients, respectively, completing the 48-week study (see online supplementary figure S1). One patient randomised to the TDF group withdrew consent before taking the study drug.
Treatment groups were comparable in regards to baseline demographic and laboratory characteristics (table 1). The mean age was 51 years and was predominantly male population (75.6%). In total, 21 (23.3%) patients had cirrhosis and 80 (88.9%) patients were HBeAg-positive. The median HBV DNA level was 4.02 log 10 IU/mL. All patients had HBV genotype C.
All patients had various combinations of resistance mutations to LAM and ETV (rtM204V/I, rtL180M, rtT184A/C/F/G/I/L/S, rtS202G and rtM250L/V; table 1), but none had HBV mutations conferring resistance to ADV (ie, rtA181V/T and/or rtN236T). Most patients (86.6%) were being treated with ETV alone or in combination with ADV at baseline. Most patients (85.6%) had been exposed to LAM and/or telbivudine before ETV.
Virological response
No significant difference in the proportion of patients who achieved a virological response at week 48, the primary efficacy end point, was observed between the two treatment arms (table 2 and figure 1). Of the patients who were randomised to TDF alone, 71.1% (32/45) had HBV DNA levels <15 IU/mL at week 48 compared with 73.3% (33/45) in those randomised to TDF+ETV ( p>0.99). The proportion of patients who achieved HBV DNA levels <60 IU/mL at week 48 was 82.2% and 88.9% in the TDF and TDF+ETV groups, respectively, and was not significantly different between the two groups ( p=0.55; table 2 and online supplementary figure S2). The mean change from baseline in serum HBV DNA levels was not significantly different between the TDF and TDF+ETV groups at week 48 (−3.66 vs −3.74 log 10 IU/mL; p=0.81; table 2 and figure 2). Of the patients who had HBV DNA detectable at week 48, the median levels of residual HBV DNA were 2.16 log 10 IU/mL (range 1.30-7.99 log 10 IU/mL) and 1.66 log 10 IU/mL (range 1.30-3.04 log 10 IU/mL) in the TDF and TDF+ETV groups, respectively ( p=0.20).
Virological response in patient subgroups
To determine the impact of baseline factors on the response to treatment, exploratory analyses were performed.
A subgroup analysis of patients who had previous exposure to ADV showed no significantly different changes in mean serum HBV DNA levels from baseline at week 48 (−3.31 vs −3.59 log 10 IU/mL; p=0.43; figure 3A ), and comparable proportion of patients who achieved a virological response at week 48 (74.3% (26 of 35) vs 66.7% (22 of 33); p=0.60; online supplementary figure S3) between the TDF (n=35) and TDF+ETV (n=33) groups. The patients who were not previously exposed to ADV also showed comparable changes in mean serum HBV DNA levels from baseline at week 48 (−4.83 vs −4.14 log 10 IU/mL; p=0.25; figure 3B ), and the proportion of patients who achieved a virological response at week 48 (60% (6 of 10) vs 91.7% (11 of 12); p=0.14; online supplementary figure S4) between the TDF (n=10) and TDF+ETV (n=12) groups.
Among patients who had a high viral load (HBV DNA levels >5 log 10 IU/mL) at baseline, the mean change in serum HBV DNA levels from baseline was comparable between the TDF (n=15) and TDF+ETV (n=10) groups (−4.72 vs −5.32 log 10 IU/mL at 48 weeks; p=0.46; online supplementary figure S5). The decline in their HBV DNA levels was slow between weeks 24 and 48 without significant difference between the two groups (median, −0.58 vs −0.89 log 10 IU/mL; p=0.51). The proportion of patients who achieved a virological response at week 48 was also comparable between the two groups (8/15 (53.3%) vs 3/10 (30%); p=0.41). Patients with a low viral load (HBV DNA levels ≤5 log 10 IU/mL) at baseline also showed comparable changes in serum HBV DNA levels in the TDF (n=30) and TDF+ETV (n=35) groups at 48 weeks (mean, −3.10 vs −3.28 log 10 IU/mL; p=0.42).
By univariate binary regression analysis, only baseline HBV DNA level was a significant predictor for virological response at 48 weeks (OR, 0.45; 95% CI 0.31 to 0.66; p<0.001; table 3). Multivariable analysis showed that previous exposure to ADV (OR, 0.13; 95% CI 0.02 to 0.73; p=0.02) and higher HBV DNA level (log 10 IU/mL) at baseline (OR, 0.32; 95% CI 0.20 to 0.53; p<0.001) were significantly associated with lower rate of virological response at 48 weeks. Treatment with TDF+ETV combination therapy was not associated with higher rate of virological response at 48 weeks (OR, 1.29; 95% CI 0.38 to 4.32; p=0.68).
Biochemical and serological responses
The proportion of patients with normal ALT levels at week 48 was comparable between the TDF and TDF+ETV groups (71.1% vs 73.3%; p=0.81; table 2). In the subset of patients with abnormal ALT at baseline, the proportion of patients that achieved ALT normalisation was also comparable between treatment groups (53.3% and 53.8% in the TDF and TDF+ETV groups at week 48, respectively; p=0.98). Among baseline factors, only high ALT level >40 IU/L and higher body mass index were significantly associated with abnormal ALT at week 48 by univariate analysis (see online supplementary table) . By multivariable analysis, baseline ALT level >40 IU/L (OR, 3.00; 95% CI 1.05 to 8.58; p=0.04) and higher body mass index (OR, 1.17; 95% CI 1.01 to 1.35; p=0.03) were independently associated with abnormal ALT at week 48.
The proportion of HBeAg-positive patients who achieved HBeAg seroclearance at week 48 was low, and no significant difference was observed between the two groups (15% vs 15%; p>0.99; table 2). No significant between-group difference was observed in the proportion of patients who achieved HBeAg seroconversion at week 48 (2.5% vs 7.5%; p=0.31; table 2). None achieved HBsAg loss or seroconversion. The median change from baseline in serum HBsAg levels was −0.28 and −0.18 log 10 IU/mL in TDF and TDF+ETV groups, respectively, without significant between-group difference ( p=0.30; online supplementary figure S6) . The number of patients who showed HBsAg level decrease from baseline≥0.5 log 10 IU/mL was 12 (26.7%) and 9 (20%) in TDF and TDF+ETV groups, respectively ( p=0.46; table 2).
Virological breakthrough and resistance surveillance
One patient in the TDF group experienced virological breakthrough at week 48 (see online supplementary figure S3 ). The virological breakthrough was transient and was associated with decreased adherence to study medication. The patient had multiple resistance mutations (rtM204V/I+rtL180M+rtM250V) prior to starting the study, and the same resistance mutations were detected during the virological breakthrough. No additional substitutions were detected in the pol/RT during virological breakthrough in this patient.
At week 48, eight and five patients in the TDF and TDF +ETV groups, respectively, had HBV DNA levels >60 IU/mL (p=0.37) and qualified for genotypic resistance analysis. The ‡Cirrhosis was diagnosed by ultrasonography with identification of liver surface nodularity and splenomegaly. §Resistance test was performed by both direct sequencing and RFMP analysis. ¶NUCs that were used >6 months. ADV, adefovir dipivoxil (10 mg/day); ALT, alanine aminotransferase; ETV, entecavir (1 mg/day); eGFR, estimated glomerular filtration rate; MDRD, modification of diet in renal disease; HBeAg, hepatitis B e antigen; HBsAG, hepatitis B surface antigen; INR, international normalised ratio; LAM, lamivudine (100 mg/day); LdT, telbivudine; NUC, nucleos(t)ide analogue; RFMP, restriction fragment mass polymorphism; TDF, tenofovir disoproxil fumarate (300 mg/day).
baseline HBV DNA levels were significantly higher in the patients who qualified for resistance analyses compared with those who did not at 48 weeks (mean, 6.13 vs 4.00 log 10 IU/mL; p<0.001). The mean change in HBV DNA levels from baseline was not different between patients who did or did not qualify for resistance analysis at week 48 (−3.17 vs −3.78 log 10 IU/mL; p=0.18). Population sequencing and RFMP analyses demonstrated that six and three patients in the TDF and TDF+ETV groups, respectively, had at least one detectable HBV resistance mutation at week 48 ( p=0.32; table 4), all of which were present prior to the initiation of TDF treatment. No patient developed additional substitutions in the pol/RT compared with those present at baseline.
Safety
Safety profiles were not significantly different between treatment groups (table 5) . No serious adverse events were judged to be related to study drug medication. Adverse events leading to study drug discontinuation or dose reduction did not occur.
A patient with cirrhosis at baseline in the TDF group was diagnosed with HCC at week 36 and was treated by surgical resection. No patient showed any signs of hepatic decompensation. A transient on-treatment ALT flare (increase of ALT>5× upper limit of normal range) was observed in two patients in the TDF group and in two patients in the TDF+ETV group, which were not associated with an increase in HBV DNA levels.
No patient experienced increases in serum creatinine levels of ≥0.5 mg/dL above baseline. The mean change in eGFR was minimal and comparable between the TDF and TDF+ETV groups throughout the 48 weeks of treatment (3.44 vs −0.12 mL/ min/1.73 m 2 ; p=0.23 at 48 weeks; online supplementary figure  S6 ). The mean change in serum phosphate was minimal and comparable between the TDF and TDF+ETV groups throughout the 48 weeks of treatment (0.13 vs −0.08 mg/dL; p=0.66 at 48 weeks; online supplementary figure S7).
Baseline DXA spine assessments revealed 7.8% (7/90) of patients with evidence of osteoporosis (T-scores below −2.5) and 33.3% (30/90) with evidence of osteopenia (T-score range, −1 to above −2.5) at baseline. The proportion of patients with osteoporosis and osteopenia at week 48 was 10.1% (9/89) and 32.6% 
DISCUSSION
This randomised trial showed that in patients with ETV-resistant HBV TDF monotherapy resulted in a comparable rate of virological response compared with that of TDF plus ETV combination therapy. At week 48, combined treatment with TDF plus ETV did not result in a higher proportion of patients with HBV DNA levels <15 IU/mL than TDF monotherapy. The reduction in mean serum HBV DNA levels during the 48 weeks of treatment was also comparable between the two groups. The virological breakthrough was rare during both treatments, which was associated with low drug adherence. Both treatments were associated with no additional emergence and a reduction in detectable HBV resistance mutations.
To the best of our knowledge, this is the first randomised trial for patients with ETV-resistant HBV. Our results are in agreement with previous in vitro studies that show that HBV strains harbouring the ETV resistance-associated substitutions, rtM204V/I, rtT184, rtS202 and/or rtM250, exhibit no crossresistance to tenofovir. 13 18 Our results are in accordance with previous case reports or retrospective cohort studies that show the clinical efficacy of TDF in ETV-resistant or ETV-refractory patients. [28] [29] [30] Our results are also similar with those of a recent 96-week single-arm trial with TDF+ETV in patients with CHB with previous NUC treatment failure. 31 For LAM-resistant patients, a combination of ADV and LAM showed no greater antiviral efficacy than ADV monotherapy. 32 Nonetheless, ADV and LAM combination therapy had been recommended for these patients to prevent additional emergence of ADV-resistant HBV mutants. 12 23 33-37 Despite the lessons drawn from the treatment of LAM-resistant patients, the situation is clearly different if TDF is used instead of ADV. Since ETV may have no or minimal antiviral efficacy in the presence of ETV-resistant HBV mutants, treatment responses to TDF and ETV combination therapy would likely be mediated by TDF alone. With this combination, continued ETV treatment would likely only help prevent the development of TDF-resistance mutations rather than increasing antiviral potency. Therefore, if there is minimal risk of TDF resistance, 10 38 the addition of ETV to TDF would theoretically provide little benefit. In fact, similar results have been observed in patients with LAM-resistant HBV. 39 The study showed that TDF monotherapy was highly efficacious in patients with LAM-resistant HBV, which was comparable to the combination of TDF and emtricitabine, without emergence of additional resistance mutations to TDF throughout 96 weeks of treatment. 38 39 Our results are similar to the previous trial for LAM-resistant patients 39 as the addition of ETV to TDF did not provide additional benefit to patients with ETV-resistant HBV. Although the majority of our patients achieved virological response at 48 weeks, the increase in proportion of patients with virological response was blunted from week 24 to week 48. This finding may raise a concern that a prolongation of therapy might not significantly increase the rate of virological response in these patients. It is especially true because even the addition of ETV to TDF in these patients was not associated with higher rate of virological response or greater reduction in serum HBV DNA levels than TDF monotherapy. Because we excluded patients who had ADV-resistance mutations and no patient had ADV-resistance mutations at week 48, the presence of ADV resistance was not suspected to have an influence on the virological response. In the exploratory analyses, only HBV DNA level at baseline and previous exposure to ADV were significantly associated with the virological response at week 48. These findings suggest that certain unidentified host factors, including the ability to efficiently convert a NUC to its active metabolite by intracellular phosphorylation pathways, might have contributed to the inability to achieve a virological response in our patients. 13 40 The influence of host factors in achieving virological response was also suspected by the relatively low HBeAg seroconversion rate (5%) in our patients compared with those of previous reports in treatment-naive patients treated with TDF (21%) or ETV (21%). 41 42 Fortunately, all compliant patients had serum HBV DNA level at very low levels (median, 1.79 log 10 IU/mL) at week 48. However, a long-term close monitoring of these patients may be required.
ADV could be a treatment option for patients with ETV-resistant HBV 12 24 because in vitro studies have demonstrated that the ETV-resistant HBV mutants remain sensitive to ADV. 13 18 However, we and others have shown that the antiviral efficacy of ADV, even in combination with ETV, was unacceptably low in ETV-resistant patients, with high rates of virological breakthrough and additional emergence of ADV resistance mutations. [19] [20] [21] Taken together, these findings suggest that TDF monotherapy would be superior to combination therapies based on ADV in ETV-resistant patients in terms of virological response and prevention of additional resistance.
Treatment with TDF and TDF+ETV was well tolerated throughout the 48 weeks, which was consistent with other prospective clinical trials of TDF in treatment-naive and LAM-resistant patients. 10 39 43 Although small decreases (mean change, <2%) in both spinal and femoral BMD were observed, they were not associated with an increased risk of fracture.
This study has a number of limitations. First, this was an open-label study and blinding was not performed. Although objective endpoints (virological, serological and biochemical) were used and drug adherence was ascertained, the lack of 
Resistance test was performed by both direct sequencing and RFMP analysis. *Between the TDF and TDF+ETV groups at 48 weeks. †This patient had rtM204V+rtL180M+rtT184A+rtS202G at baseline. ETV, entecavir; RFMP, restriction fragment mass polymorphism; TDF, tenofovir disoproxil fumarate. †TDF group: gastric polyp bleeding, variceal bleeding, acute pancreatitis, inguinal hernia, herniation of intervertebral disc, subarachnoid haemorrhage by traffic accident and acute enteritis; TDF+ETV group: pancreatic serous cystadenoma, retinal detachment, finger injury and intestinal stricture. None were judged to be related to study drug administration. ‡Hepatocellular carcinoma was diagnosed at week 36 and was treated by surgical resection. §ALT flare was defined as increase of ALT>×5 upper limit of normal. All ALT flares were transient and improved with continued treatment. ¶This patient entered the study with low baseline eGFR (49 mL/min/1.73 m 2 ) and had eGFR 41 mL/min/1.73 m 2 at week 48. TDF dose was not modified in this patient throughout the study period. **Serum phosphate decreased to 1.9 mg/dL at week 4 from 2.4 mg/dL at baseline, and then increased to above 2.0 mg/dL without dose reduction of TDF or supplementation of phosphate. ALT, alanine aminotransferase; eGFR, estimated glomerular filtration rate; ETV, entecavir; TDF, tenofovir disoproxil fumarate.
blinding might have affected the attention of the study patients or biased the investigators in reporting the adherence and adverse events. Second, the predominant population had relatively low HBV DNA levels at baseline. This may be associated with the decreased replicative fitness of drug-resistant HBV and the partially effective ongoing therapies in our patients. 13 Although subgroup analyses of patients with high viral loads also showed no difference in the change in HBV DNA levels between TDF and TDF+ETV groups, the number of patients was small. It was shown that the combination therapy could provide a benefit to patients with baseline levels of HBV DNA >10 8 IU/mL. 43 The baseline HBV DNA of our patients might be too low to see such a difference. Lastly, the duration of treatment (48 weeks) was relatively short. In this regard, a longer follow-up assessment period would be warranted. With longer duration of treatment, the proportion of patients with virological response and HBeAg seroconversion might increase, as shown by a recent 96-week single-arm trial with TDF+ETV in patients with CHB with previous NUC treatment failure. 31 The primary goal of therapy for CHB is to prevent liver disease progression, and seroclearance or seroconversion of HBsAg is regarded as an optimal endpoint of treatment. 44 However, HBsAg seroclearance occurs very rarely with NUC treatment. 44 Long-term HBV DNA and HBsAg level kinetics in patients with CHB treated with potent NUCs showed that HBsAg clearance is unlikely to occur during the patient's lifetime, even if HBV replication is well controlled. 45 Thus, long-term, almost indefinite, NUC treatment is required for the majority of patients. In patients with ETV-resistant HBV, a combination of TDF and ETV would be potentially safe to prevent the emergence of resistance to TDF. 46 However, long-term tolerance data are lacking and cost may be an issue for this combination. Considering a comparable antiviral efficacy, extremely low risk of TDF resistance, and lower cost, TDF monotherapy would be a reasonable option for the treatment of ETV-resistant patients.
In conclusion, TDF monotherapy for 48 weeks provided a comparable rate of virological response compared with TDF plus ETV combination therapy in heavily pretreated patients with ETV-resistant HBV viraemia. No additional HBV resistance mutations were observed in either the TDF monotherapy or TDF plus ETV combination therapy patients. These results support the view that TDF monotherapy may be a treatment option for patients with ETV-resistant HBV.
